BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32934653)

  • 1.
    Chang XY; Wu Y; Jiang Y; Wang PY; Chen J
    Gastroenterol Res Pract; 2020; 2020():1457452. PubMed ID: 32934653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    Springerplus; 2016; 5(1):1172. PubMed ID: 27512631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
    Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
    J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.
    Basturk O; Tan M; Bhanot U; Allen P; Adsay V; Scott SN; Shah R; Berger MF; Askan G; Dikoglu E; Jobanputra V; Wrzeszczynski KO; Sigel C; Iacobuzio-Donahue C; Klimstra DS
    Mod Pathol; 2016 Sep; 29(9):1058-69. PubMed ID: 27282351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNF43 mutation frequently occurs with GNAS mutation and mucin hypersecretion in intraductal papillary neoplasms of the bile duct.
    Tsai JH; Liau JY; Yuan CT; Cheng ML; Yuan RH; Jeng YM
    Histopathology; 2017 Apr; 70(5):756-765. PubMed ID: 27864998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of GNAS and KRAS mutations in pancreatic cysts.
    Lee LS; Doyle LA; Houghton J; Sah S; Bellizzi AM; Szafranska-Schwarzbach AE; Conner JR; Kadiyala V; Suleiman SL; Banks PA; Andruss BF; Conwell DL
    JOP; 2014 Nov; 15(6):581-6. PubMed ID: 25435574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and clinicopathological features of appendiceal mucinous neoplasms.
    Yanai Y; Saito T; Hayashi T; Akazawa Y; Yatagai N; Tsuyama S; Tomita S; Hirai S; Ogura K; Matsumoto T; Wada R; Yao T
    Virchows Arch; 2021 Mar; 478(3):413-426. PubMed ID: 32821969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.
    Yang CY; Huang WJ; Tsai JH; Cheng A; Chen CC; Hsu HP; Jeng YM
    Mod Pathol; 2019 Nov; 32(11):1637-1645. PubMed ID: 31231124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study to evaluate tissue- and plasma-based DNA driver mutations in a cohort of patients with pancreatic intraductal papillary mucinous neoplasms.
    Park MA; Zaw T; Yoder SJ; Gomez M; Genilo-Delgado M; Basinski T; Katende E; Dam A; Mok SRS; Monteiro A; Mohammadi A; Jeong DK; Jiang K; Centeno BA; Hodul P; Malafa M; Fleming J; Chen DT; Mo Q; Teer JK; Permuth JB
    G3 (Bethesda); 2023 Feb; 13(2):. PubMed ID: 36454217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraductal Papillary Neoplasm of Bile Duct: Updated Clinicopathological Characteristics and Molecular and Genetic Alterations.
    Nakanuma Y; Uesaka K; Kakuda Y; Sugino T; Kubota K; Furukawa T; Fukumura Y; Isayama H; Terada T
    J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33317146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas.
    Sakamoto H; Kuboki Y; Hatori T; Yamamoto M; Sugiyama M; Shibata N; Shimizu K; Shiratori K; Furukawa T
    Mod Pathol; 2015 Feb; 28(2):261-7. PubMed ID: 25081753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How does intestinal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression.
    Omori Y; Ono Y; Kobayashi T; Motoi F; Karasaki H; Mizukami Y; Makino N; Ueno Y; Unno M; Furukawa T
    Virchows Arch; 2020 Jul; 477(1):21-31. PubMed ID: 32291497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms.
    Huang B; Trujillo MA; Fujikura K; Qiu M; Chen F; Felsenstein M; Zhou C; Skaro M; Gauthier C; Macgregor-Das A; Hutchings D; Hong SM; Hruban RH; Eshleman JR; Thompson ED; Klein AP; Goggins M; Wood LD; Roberts NJ
    J Pathol; 2020 Nov; 252(3):252-262. PubMed ID: 32696980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fundic gland differentiation of oncocytic/pancreatobiliary subtypes of pancreatic intraductal papillary mucinous neoplasm.
    Mamat O; Fukumura Y; Saito T; Takahashi M; Mitomi H; Sai JK; Kawasaki S; Yao T
    Histopathology; 2016 Oct; 69(4):570-81. PubMed ID: 26990132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GNAS but Not Extended RAS Mutations Spectrum are Associated with a Better Prognosis in Intraductal Pancreatic Mucinous Neoplasms.
    Gaujoux S; Parvanescu A; Cesaretti M; Silve C; Bieche I; Rebours V; Lévy P; Sauvanet A; Cros J
    Ann Surg Oncol; 2019 Aug; 26(8):2640-2650. PubMed ID: 31025231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas.
    Furukawa T; Kuboki Y; Tanji E; Yoshida S; Hatori T; Yamamoto M; Shibata N; Shimizu K; Kamatani N; Shiratori K
    Sci Rep; 2011; 1():161. PubMed ID: 22355676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.